Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
testalize-me-0jE8ynV4mis-unsplash
Oryzon Genomics (BME: ORY) doses first patient in new MDS trial
Published by Arron Aatkar, PhD

Oryzon Genomics has announced that the first patient has been dosed in its new Phase Ib trial in myelodysplastic syndrome (MDS), led by the Medical College of Wisconsin. This study (NCT06502145) aims to evaluate the safety, tolerability and recommended Phase II dose of iadademstat when administered in combination with the standard-of-care, azacitidine, in adults with MDS.

Latest

Industrials | Comment

Smiths News (LON: SNWS) – In-line trading update

Industrials | Comment

Dialight (LSE: DIA) – Q326 trading update

Investment Companies | Comment

BB Biotech (SIX: BION) reports preliminary FY25 results